Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioMarin Pharmaceutical's Total Assets for the quarter that ended in Mar. 2026 was €7,431 Mil.
During the past 12 months, BioMarin Pharmaceutical's average Total Assets Growth Rate was 8.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 5.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 5.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 8.00% per year.
During the past 13 years, BioMarin Pharmaceutical's highest 3-Year average Total Assets Growth Rate was 65.40%. The lowest was -3.30%. And the median was 14.30%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
BioMarin Pharmaceutical's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
BioMarin Pharmaceutical Total Assets Related Terms
BioMarin Pharmaceutical Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
BioMarin Pharmaceutical's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (HAM:BM8) has a Total Assets of €7,431 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Total Assets too high?
BioMarin Pharmaceutical's current Total Assets is €7,431 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Total Assets compare to CYTK and ARWR?
BioMarin Pharmaceutical's Total Assets of €7,431 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Total Assets is €7,431 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
BioMarin Pharmaceutical (HAM:BM8) has a current Total Assets of €7,431 Mil. The stock's GF Value™ is €75.78, compared to a current price of €52.16 — trading 31.2% below its estimated fair value. The current Total Assets is €7,431 Mil. BioMarin Pharmaceutical's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For BioMarin Pharmaceutical (HAM:BM8), the current Total Assets is €7,431 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of €52.16 is trading 31.2% below its estimated GF Value™ of €75.78.
Key valuation signals for HAM:BM8:
Total Assets: €7,431 Mil
GF Value™: €75.78 vs. price of €52.16 (31.2% below fair value)
No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
75GF Score
Get the complete analysis for HAM:BM8
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BM8 has been successfully added to your 
